AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03511261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Group 4 placebo capsules for oral intake two times per day
Study NCT03042013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8273
Description: Oral
Study NCT04474145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PT group
Description: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
Study NCT00427154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: Tablets, 4 mg once or twice daily.
Study NCT00427154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, inhalation.
Study NCT00427154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 2000 mg/day.
Study NCT00427154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Tablets, 8 mg/day.
Study NCT02305407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Revascularization
Description: Most patients in this group will be performed combined procedures of superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis (EDMS). Patients not suitable for combined procedures will be performed EDMS.
Study NCT02305407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Description: Patients will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
Study NCT04077125 — intervention group
Intervention type: DRUG
Intervention: Rifaximin
Description: to investigate changes in cerebral, splanchnic hemodynamics and endothelial function in cirrhotic patients with MHE after 15 days of rifaximin therapy (1200 mg/d)
Study NCT01228552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical, intra-oral ketoprofen gel
Description: Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
Study NCT01228552 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
Study NCT00486434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMC021 Oral Calcitonin
Description: 0.8mg SMC021 (Oral Calcitoinin) twice daily
Study NCT00486434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SMC021 Placebo
Description: Placebo orally, twice daily
Study NCT01724762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Orientation
Description: * Control group: patients who did not read the informative manual concerning bed bath and received only the unit's routine information~* Intervention group: patients who received nursing orientation and read the informative manual concerning bed bath
Study NCT04416854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of primary tumor
Description: resection of primary lesion with unresectablely metastatic colon cancer
Study NCT04416854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
Study NCT04416854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
Study NCT04416854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1
Study NCT04416854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1
Study NCT02940652 — intervention group
Intervention type: RADIATION
Intervention: Magnetic resonance imaging
Description: No intervention - description of the position of the LMA obtained during routine elective MRI scanning of the brain and/or cervical spine
Study NCT04470739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: chest x-ray
Description: First Chest X-ray in the first 6 hours of infants
Study NCT04381741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-7×19 CAR-T plus PD1 monoclonal antibody
Description: Three different doses of CD19-7×19 CAR-T (1×106/kg、2×106/kg、3×106/kg) plus 200mg Tislelizumab every 3 weeks for 6 times
Study NCT03545334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD)
Description: Injection of ICG intradermally around the scar of the primary excision of the tumour and transcutaneous assessment of fluorescence with the VS3-3DHD camera (Visionsense™ VS3 - Stereoscopic High Definition Visualisation System ).
Study NCT03292263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: iv infusion 70-100 mg/m2 on day -3, -2
Study NCT03292263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: iv infusion 100 mg on day -3, +17
Study NCT03292263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: peripheral blood stem cell transfusion at day 0
Study NCT03703206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK)
Description: nerve block for posterior knee pain after a TKA.
Study NCT01186861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Tablet administered with food and with up to 200 mL of water
Study NCT01186861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Tablet administered at least 2 hours after food with up to 200 mL of water
Study NCT01186861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erlotinib
Description: Tablet administered at least 2 hours after food with up to 200 mL of water
Study NCT03318289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ving Tsun
Description: The VT training regimen is designed to improve reactive balance control, lower extremity muscle strength and balance confidence in the elderly. It comprises 9 VT sticking-hand drills that must be practised with a partner. Participants will be trained to respond rapidly to upper body perturbations and to maintain body balance. Those joined the VT training group will attend a one-hour supervised VT training session at an elderly community centre 2 times per week for 12 weeks.
Study NCT01186861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablet administered at least 2 hours after food with up to 200 mL of water
Study NCT02944799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Discontinuation of alendronate treatment
Study NCT02944799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Study NCT02944799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Daily dietary supplement of 800mg calcium
Study NCT02944799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: Daily dietary supplement of 800mg calcium
Study NCT02944799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Daily dietary supplement of 38 micrograms vitamin D
Study NCT02944799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Daily dietary supplement of 38 micrograms vitamin D
Study NCT04527172 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: neuromuscular ultrasound
Description: ultrasound to visualize the peripheral nerves of lupus patients and to compare it with results of the raditional electrophysiological studies
Study NCT01293396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Patients received insulin aspart before breakfast and before lunch.
Study NCT01293396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart 30
Description: Patients received biphasic insulin aspart 30 before breakfast and before lunch.
Study NCT01293396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart 70
Description: Patients received biphasic insulin aspart 70 before breakfast and before lunch.
Study NCT04207567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bodyweight exercises (push-ups, angled-rows, bodyweight squats) on weekdays
Description: Participants will be instructed to perform one set each of push-ups, angled-rows, and bodyweight squats every weekday. They will be given the equipment and training necessary to properly perform the exercises. They will also be trained in the Tiny Habits® Method and receive digital coaching.
Study NCT02639117 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vismodegib
Description: Vismodegib 150 mgs po qd for 3 months
Study NCT00390780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miconazole Lauriad
Description: 50 mg buccal tablet once a day for 14 days
Study NCT00390780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: 10mg troches administered Five Times a Day for 14 days
Study NCT03179098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Weeks protocol
Description: The modified Weeks group (GWM) will apply the protocol suggested by Flowers (2002), the positioning will be maintained and at rest will be done electromyographic registers, active goniometry and EVA. Soon afterwards the patients will be submitted to the whirlwind for 20 minutes at a temperature of 41 ° C performing active flexion and elbow extension movements. After the swirl the patients will be submitted to a stretching maintained for 10 minutes with load proportional to the force captured during MVIC according to the pain of the patient. The load will be positioned through a leather device 20 cm from the lateral epicondyle of the elbow.
Study NCT03179098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIVM
Description: Patients underwent electromyographic analysis for the determination of maximal voluntary isometric contraction. The force will be collected for 5 seconds during a CIVM, in which a load cell model MM50 (Kratos, Cotia, SP, Brazil) will be positioned between the floor and the forearm of the volunteer, being coupled to a leather device at 20 cm Make the lateral epicondyle of the elbow. The angle between the forearm and the cable containing a load cell with a 90 degree service.
Study NCT03179098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GC- Sustained Stretching
Description: The control group will be applied to sustained stretching, patients will be placed in the supine position with abduction of the shoulder of 30 ° in the plane of the scapula and the forearm in neutral throughout the entire test and the elbow will be supported in a towel to avoid discomfort And compression in the region of the olecranon.
Study NCT02003742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1207
Description: Single TRUS-guided intraprostatic injection of 2.5 mg of NX-1207
Study NCT02003742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 1 film coated, prolonged release tablet of tamsulosin 0.4 mg, to be taken orally (p.o.) QD
Study NCT00620620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Inhaled Staccato Placebo
Study NCT00620620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Zaleplon 0.5 mg
Description: Inhaled Staccato Zaleplon 0.5 mg
Study NCT00620620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Zaleplon 1 mg
Description: Inhaled Staccato Zaleplon 1 mg
Study NCT00620620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Zaleplon 2 mg
Description: Inhaled Staccato Zaleplon 2 mg
Study NCT00620620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Zaleplon 4 mg
Description: Inhaled Staccato Zaleplon 4 mg
Study NCT01454401 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LeucoPatch treatment
Description: weekly
Study NCT00278265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX followed by fludarabine
Description: MTX should be administered with 10-20mg weekly, calculated according to the body weight. Fludarabine should be administered with 25mg/m2 on day 1-3 of 28 days, up to 4 cycles
Study NCT01101386 — intervention group
Intervention type: DRUG
Intervention: Voriconazole
Description: Patients will be started on voriconazole 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h thereafter.
Study NCT00396630 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rotarix
Description: Two-dose oral vaccination.
Study NCT00396630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Two-dose oral vaccination.
Study NCT00396630 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two-dose oral administration.
Study NCT04551183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgeons CT scan analysis
Description: Surgeons extract diameter by hand (Gold Standard method) then realised a semi-manual segmentation of the images to extract volumes and diameters of the aorta (espacially AAA)
Study NCT04551183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRAEVAorta CT scan analysis
Description: CT scans are analysed by the software under investigation : PRAEVAorta. It will extract volumes and diameters of the aorta (AAA espacially)
Study NCT04049097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Description: 2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
Study NCT03474393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: systematic intensive therapy
Description: intensive telephone och internet Contact with diabetes nurse for coaching and guidance over 4 months and 4 Control visits
Study NCT03727763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960mg po bid
Study NCT03727763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500mg/m2 iv gtt (14 days per course)
Study NCT03313895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic & Cognitive Training (ACT)
Description: ACT stands for combined aerobic exercise and cognitive training.
Study NCT03313895 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cycling Only
Description: Cycling on a recumbent stationary cycle
Study NCT03313895 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training Only
Description: Engage in cognitive training on a computer
Study NCT03313895 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stretching and Mental Stimulating Activities
Description: Stretching exercises and mental stimulating activities on a computer
Study NCT01881763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 1-2 mgr/ kg IV
Study NCT01881763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methohexital
Description: Methohexital 0.5-1mg/kg IV
Study NCT04404569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion in 28-day cycles
Study NCT04081896 — intervention group
Intervention type: OTHER
Intervention: Exercise
Description: Exercise prescribed to participants includes spine-specific strengthening exercises targeting core musculature (i.e. Multifidus, Erector Spinae, Transversus Abdominus, Obliques, and Rectus Abdominus). The in-clinic exercise program recommends a minimum of 20 visits at 2 visits/week, with a goal of 24 total visits over a 12-week period. Exercise is progressed by 5-10% of their exercise load once they are able to do >20 repetitions. If they are able to reach >10 but \<20 repetitions, exercise load remains the same. If they are unable to reach 10 repetitions, exercise load is decreased 5-10% at their next visit.~The online exercise program includes non-machine based home exercises targeting the same muscles of interest, and are personalized to each participant based on their home resources and comfort level.~Concurrent interventions may or may not include nutrition education, mindfulness, cognitive behavioral therapy.
Study NCT03828773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Posaconazole
Description: Posaconazole is a triazole with broad-spectrum activity, to include Candida species, Aspergillus species, and other fungal pathogens, including the Zygomycetes. Posaconazole is available as slow release tablets (300mg/day) and as intravenous (IV) formulation (300mg/day) and is licensed and approved in Switzerland for the prevention of IFI, including mold and yeast infections, in patients >18 years who are at high risk of developing these types of infection (patients with long-term neutropenia or HCT recipients). Furthermore, international guidelines recommend posaconazole for primary antifungal prophylaxis in high-risk patients, such as AML patients with prolonged neutropenia. Posaconazole is available in Switzerland under the name of Noxafil® in capsules of 100mg, suspension of 40mg/mL and intravenous formulation of 300mg/16.7 mL.
Study NCT03828773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole
Description: Fluconazole is an antifungal with activity against most Candida species. Fluconazole is licensed and approved in Switzerland for prophylaxis of IC in patients with neutropenia induced by chemotherapy or radiotherapy at a daily dose of 200 to 400 mg once daily. Fluconazole (200 mg or 400 mg once daily) is still currently used as primary antifungal prophylaxis (standard of care) in all 7 centers participating in this trial. Fluconazole is available in Switzerland under the name of Diflucan® in capsules of 50 mg, 150 mg and 200 mg and in powder for preparation of suspension (50 mg/5 ml and 200 mg/5 ml (forte)) or perfusion (2 mg/1 ml). Several generics of Diflucan® are authorized in Switzerland. Prescribing Diflucan® or any of its generics will remain at the discretion of and based on the standard operating procedures (SOP) at each institution.
Study NCT01329484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy
Description: Personalized reminiscence therapy using a computerized system
Study NCT01329484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training using a computerized system
Study NCT01329484 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: Participants in the control group will receive neither of the 2 experimental interventions or any other similar interventions.
Study NCT03271229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Concentrated Bone Marrow Aspirate (BMAC)
Description: Participants will have a knee injected with BMAC stem cells harvested from the iliac crest
Study NCT02337504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: community-based care
Description: Will receive HIV care in the community and not in the clinic which is the normal standard of care
Study NCT03649178 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: salt
Description: Participants will randomly eat a high salt diet for 8 weeks and a low salt diet for 8 weeks
Study NCT01062646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal music therapy
Study NCT01062646 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community treatment as usual
Study NCT02495649 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: [18F]-DOPA
Description: To evaluate the feasibility of PET-CT with \[18F\]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
Study NCT02495649 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET-CT
Description: To evaluate the feasibility of PET-CT with \[18F\]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
Study NCT00780468 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Existing diet plan
Study NCT00780468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New diet plan
Study NCT02691247 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLBS03 Low Dose
Study NCT02691247 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLBS03 High Dose
Study NCT02691247 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo